HLA-DQB1 and acute myeloid leukemia: Whether the peptide is a neoantigen that can be targeted on AML by immunotherapy, for example by T cells engineered with TCRs of our RUNX1-specific clones, requires further testing of T cell clones against HLA-DQB1*03:02 positive patient-derived AML samples carrying RUNX1 frameshift mutations, which were not available in our biobank and could not be easily collected.